Mark Lampert‘s Biotechnology Value Fund LP recently filed a 13G with the US SEC to report lowering its stake in Tobira Therapeutics Inc. (NASDAQ:TBRA) to 399,433 shares, which amass 2.1% of the float. The stake was lowered from 2.14 million shares which Biotechnology Value Fund previously held, which accounted for 11.4% of the company’s outstanding stock, as per its previous 13G filing on the company.
Tobira Therapeutics, formerly Regado Biosciences, is a biopharmaceutical company that develops therapies to help treat patients who suffer from liver disease, inflammation fibrosis, and HIV. On September 20, Tobira signed an agreement with Allergan plc (NYSE:AGN) to be acquired by the company for a total sum of around $1.7 billion. Year-to-date, Tobira’s stock is up by a massive 293.03%.
bikeriderlondon/Shutterstock.com
Seven of the hedge funds that we track were long Tobira Therapeutics Inc. (NASDAQ:TBRA) on June 30, down by two during the second quarter. Lampert’s fund had the largest position among the funds in our database, valued at $15.74 million, while Paul Marshall and Ian Wace’s Marshall Wace LLP, and Israel Englander’s Millennium Management also held positions worth more than a million dollars. Brian Ashford-Russell and Tim Woolley’s Polar Capital sold off its 50,000-share stake in the second quarter.
Follow Tobira Therapeutics Inc. (NASDAQ:TBRA)
Follow Tobira Therapeutics Inc. (NASDAQ:TBRA)
Receive real-time insider trading and news alerts
You can access the original SEC filing by clicking here.
Ownership Summary Table
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| Biotechnology Value Trading Fund OS | 0 | 33,627 | 0 | 33,627 | 33,627 | Less than 1% |
| BVF Partners OS Ltd | 0 | 33,627 | 0 | 33,627 | 33,627 | Less than 1% |
| BVF Partners | 0 | 399,433 | 0 | 399,433 | 399,433 | 2.1% |
| BVF Inc | 0 | 399,433 | 0 | 399,433 | 399,433 | 2.1% |
| Mark N. Lampert | 0 | 399,433 | 0 | 399,433 | 399,433 | 2.1% |
Follow Mark Lampert's Biotechnology Value Fund / BVF Inc
Page 1 of 11 – SEC Filing
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
| Tobira Therapeutics, Inc. |
| (Name of Issuer) |
| Common Stock, par value $0.001 |
| (Title of Class of Securities) |
| 88883P 10 1 |
| (CUSIP Number) |
| September 20, 2016 |
| (Date of Event Which Requires Filing of this Statement) |
| o | Rule 13d-1(b) |
| x | Rule 13d-1(c) |
| o | Rule 13d-1(d) |
_______________
Follow Tobira Therapeutics Inc. (NASDAQ:TBRA)
Follow Tobira Therapeutics Inc. (NASDAQ:TBRA)
Receive real-time insider trading and news alerts
